dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wiendl, Heinz |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Alvarez, Enrique |
dc.contributor.author | Davydovskaya, Maria |
dc.contributor.author | Delgado, Silvia R |
dc.contributor.author | Bar-Or, Amit |
dc.date.accessioned | 2022-07-19T10:25:42Z |
dc.date.available | 2022-07-19T10:25:42Z |
dc.date.copyright | 2021 |
dc.date.issued | 2022-05 |
dc.identifier.citation | Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910–24. |
dc.identifier.issn | 1477-0970 |
dc.identifier.uri | https://hdl.handle.net/11351/7819 |
dc.description | Ofatumumab; Esclerosi múltiple; Farmacocinètica |
dc.description.sponsorship | The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the APLIOS trial was funded by Novartis Pharmaceuticals. Novartis Pharmaceuticals supported the development of this manuscript, provided data analyses according to the direction of the authors, and paid for medical writing support. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Multiple sclerosis;28(6) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple |
dc.subject | Anticossos monoclonals |
dc.subject | Injeccions hipodèrmiques |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /chemically induced |
dc.title | Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/13524585211044479 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /inducido químicamente |
dc.relation.publishversion | https://doi.org/10.1177/13524585211044479 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bar-Or A] Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [Wiendl H] Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. [Montalban X] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Alvarez E] Department of Neurology, Rocky Mountain MS Center, University of Colorado, Aurora, CO, USA. [Davydovskaya M] Pirogov Russian National Research Medical University, Moscow, Russian Federation. [Delgado SR] MS Center and Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA |
dc.identifier.pmid | 34605319 |
dc.identifier.wos | 000715307700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |